2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3698 A phase 2 investigator initiated trial of loncastuximab tesirine and mosunetuzumab in patients with relapsed/refractory diffuse large B-cell lymphoma

Swetha Thiruvengadam, MD, Lu Chen, PhD2, Tycel Phillips, MD, FASCO3, Avyakta Kallam, MBBS4, Azra Borogovac, MD5, Matthew Mei I, MD6, John Baird, MD7, Alexey V. Danilov, MD, PhD8, Christina Poh, MD9, Brian Sworder, MD, PhD10, Geoffrey Shouse, DO PhD11, Jennifer Shepphird, PhD12, Saida Benavides13, Jessi Diaz14, Steven T Rosen, MD15, Joo Song, MD16, Alex Francisco Herrera, MD17, L. Elizabeth Elizabeth Budde, MD PhD18
1 City of Hope National Medical Center, Duarte, United States
2 City of Hope National Medical Center, Duarte, United States
3 City of Hope National Medical Center, Duarte, United States
4 City of Hope National Medical Center, Duarte, United States
5 City of Hope National Medical Center, Duarte, United States
6 City of Hope National Medical Center, Duarte, United States
7 City of Hope National Medical Center, Duarte, United States
8 City of Hope National Medical Center, Duarte, United States
9 City of Hope National Medical Center, Duarte, United States
10 City of Hope National Medical Center, Duarte, United States
11 City of Hope National Medical Center, Duarte, United States
12 City of Hope National Medical Center, Duarte, United States
13 City of Hope National Medical Center, Duarte, United States
14 City of Hope National Medical Center, Duarte, United States
15 City of Hope National Medical Center, Duarte, United States
16 City of Hope National Medical Center, Duarte, United States
17 City of Hope National Medical Center, Duarte, United States
18 City of Hope National Medical Center, Duarte, United States

While Chimeric Antigen Receptor T-cell Therapy (CAR-T) leads to durable responses in patients (pts) with R/R DLBCL, most pts will ultimately relapse with poor survival outcomes. Improved therapy for R/R DLBCL remains an unmet need. Bispecific antibodies and antibody drug conjugates have been combined with promising results. Here we present an interim analysis of a phase 2 study (NCT05672251) evaluating the efficacy and safety of loncastuximab tesirine (Lonca) + mosunetuzumab (Mosun) in R/R DLBCL, enabling targeting of both CD19 and CD20 with agents that have distinct but potentially complementary mechanisms of action.

 

Adult pts with R/R DLBCL after ≥1 prior line of therapy with measurable disease and biopsy proven CD20 expression at relapse were enrolled. Lonca was given intravenously every 3 weeks starting C1 (150ug/mg then 75ug/mg) for 8 cycles and Mosun after standard pre-medications was given intravenously weekly during C1 with step-up dosing (1mg, 2mg, 60mg) and every 3 weeks (60mg) starting C2, for a total of 8-17 cycles of study treatment (txt) based on timing of best response, unacceptable toxicity, or disease progression (PD).  Response was assessed per Lugano 2014 criteria. The primary objective was to assess efficacy by overall response rate (ORR) and secondary objectives included complete response rate (CRR), progression-free survival (PFS), as well as safety of the combination. A Simon two stage Minimax design was used (N=26; H0 40%, HA 65%, power 81%, alpha level 0.047; stage 1= 12 pts).

 

Twenty-five pts enrolled between 1/2024 and 4/2026. Median age was 74 (range 49-84), 12 (48%) female, 9 (36%) Hispanic, 18 (72%) had advanced stage disease, 15 (60%) had R-IPI 3-5, with median 2 prior lines (range 1-5) and 13 (52%) had prior CAR T. Median number of cycles was 6 (range 1-12). Of the 25 enrollments, 6 completed txt, 14 terminated txt prior to completion due to PD (n=9), death (n=2), MD decision (n=2), and patient refusal (n=1), and 5 are still on study txt.

 

Twenty-five pts were evaluable for toxicity. The most common any grade txt-related AEs (TrAEs) were anemia (52%), neutropenia (40%), thrombocytopenia (32%), elevated ALP (36%), elevated AST/ALT (36%), cutaneous toxicity (36%), nausea (28%), lymphopenia (28%), fatigue (24%), fever (24%), hyponatremia (24%), constipation (20%), localized edema (20%), hyperglycemia (20%), and dyspnea (20%). The most frequent G3-4 TrAEs were neutropenia (20%), lymphopenia (20%), and lung infection (16%). One pt (4%) had G1 cytokine release syndrome (CRS) but did not require tocilizumab or steroids. Infection was observed in 8 (32%) pts, out of which 5 (20%) were ≥ grade 3, including 1 (4%) with G5 sepsis. No ICANS or febrile neutropenia was observed. A serious adverse event (SAE) was observed in 12 (48%) pts. Seven (28%) pts discontinued single-agent Lonca early, receiving a median of 5 (range 3-7) cycles, due to toxicities: skin rash (n=1), transaminitis (n=2), fatigue (n=1), peripheral edema (n=1), combination of edema/effusion and transaminitis (n=1), and combination of peripheral/facial edema and rash (n=1).

 

Of the 25 pts, 3 pts received < 2 cycles due to clinical PD at C1 (n=2) and death at C1 (n=1, sepsis), and were deemed non-response-evaluable and replaced. Of the other 22 pts, all but two have available response data. The best ORR was 85% (17/20) and best CRR was 50% (10/20). Most responses were observed at the time of the first disease assessment following C4, with 1 pt converting from PR to CR at C8. Of the 22 response-evaluable pts, 8 experienced PD, all during txt. Eight pts died on study, 6 due to PD, one due to respiratory failure from presumed aspiration pneumonitis, and one due to failure to thrive. Median follow-up among the 14 response-evaluable survivors is 5.7m. Median PFS for the 22 response-evaluable pts is 7.0m (95%CI: 4.4-NA) and median OS is 11.9m (95%CI: 6.2-NA). Among the 17 responders, median duration of response is 7.7m (95%CI: 2.7-NA). Among the 10 pts with CR, 1 had subsequent PD, with a median duration of CR not reached.

 

Lonca-Mosun resulted in objective responses in a majority of pts with a subset of pts experiencing deep and durable remission. The toxicity profile of the combination was similar to what has been previously observed with each drug, with frequent infections and cytopenias, although the rate of SAE was high. Longer follow-up is needed to evaluate the durability of responses.

Swetha Thiruvengadam, MD: Innate Pharma SA - Honoraria; ADC Therapeutics - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Innate Pharma SA - Consultancy (Includes expert testimony)